Alterity Therapeutics Limited
NASDAQ:ATHEBiotechnology
+$0.53 today
- Market cap
- $52.77M
- Beta
- -0.03
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.07
Volume 0.02M
Average 0.05M
ATHE Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Alterity Therapeutics LimitedNASDAQ: ATHE
Other Income / Expenses · Q2 FY2026 · quarter ended Dec 2025
Other income / expenses turns positive
Q2 FY2026 other income / expenses was A$686.86K, compared with -A$1.29M a year earlier. Over 3 fiscal years it compounded at -2.9% a year.
Context
- Other income / expenses amounted to 45.9% of revenue in FY2025, up 32.8 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
AUD · from the income statement
- Latest · FY2025
- 2.49M AUD
- Year-over-year change
- +375.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 2.49M | +375.7% |
| FY2024 | 2024-06-30 | 524.33K | -42.0% |
| FY2023 | 2023-06-30 | 904.68K | -66.8% |
| FY2022 | 2022-06-30 | 2.72M | +2147.4% |
| FY2021 | 2021-06-30 | (133.04K) | — |
Other Income / Expenses vs competitors
How ATHE compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +375.7% is the highest of 4, against a peer median of +112.9%.
- Other income / expenses amounts to 45.9% of revenue for ATHE, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | A$2.49M AUD | +375.7% | -2.9% | 45.9% | |
| LTM Mar 2026 | $1.55M USD | +221.6% | +66.4% | — | |
| LTM Mar 2026 | $501.25K USD | +112.9% | +66.3% | — | |
| LTM Mar 2026 | -$200.08K USD | -305.0% | — | 6.7% | |
| Peer median (excluding ATHE) | — | +112.9% | +66.4% | 6.7% | |
Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 4.34M | 5.12M | 3.92M | 4.02M | 5.44M |
| Cost of Revenue | 360.03K | 364.67K | 285.07K | 214.3K | 127.52K |
| Gross Profit | 3.98M | 4.76M | 3.63M | 3.8M | 5.31M |
| Gross Margin | 91.7% | 92.9% | 92.7% | 94.7% | 97.7% |
| Research & Development | 12.28M | 14.75M | 13.2M | 18.64M | 14.4M |
| Selling, General & Admin | 6.87M | 5.51M | 5.04M | 4.76M | 5.48M |
| Operating Expenses | 19.16M | 20.26M | 18.24M | 23.41M | 19.89M |
| Depreciation & Amortization | 18.66K | 54.21K | 37.85K | 35.34K | 28.31K |
| EBITDA | (15.16M) | (17.39M) | (14.6M) | (19.57M) | (14.63M) |
| EBITDA Margin | -349.3% | -339.5% | -372.8% | -486.9% | -269.0% |
| Operating Income | (15.18M) | (15.5M) | (14.64M) | (19.6M) | (14.57M) |
| Operating Margin | -349.8% | -302.6% | -373.7% | -487.7% | -268.0% |
| Interest Income | 20.68K | 2.5K | 16.44K | 268.42K | 446.29K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (133.04K) | 2.72M | 904.68K | 524.33K | 2.49M |
| Income Before Tax | (15.31M) | (12.78M) | (13.7M) | (19.08M) | (12.08M) |
| Pre-Tax Margin | -352.8% | -249.4% | -349.9% | -474.6% | -222.1% |
| Income Tax Expense | (3.08M) | 70.01K | 104.46K | 46.09K | 68.06K |
| Net Income | (15.31M) | (12.85M) | (13.81M) | (19.12M) | (12.15M) |
| Net Margin | -352.8% | -250.7% | -352.5% | -475.8% | -223.4% |
| EPS (Basic) | (5.40) | (3.18) | (3.42) | (3.12) | (1.14) |
| EPS (Diluted) | (5.40) | (3.18) | (3.42) | (3.12) | (1.14) |
| Weighted Avg Shares | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
| Weighted Avg Shares (Diluted) | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
Alterity Therapeutics Limited
NASDAQ:ATHE
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.